Ocumension Therapeutics
Ocumension Therapeutics, a leading biopharmaceutical company headquartered in China, focuses on innovative therapies for ophthalmic diseases. Founded in 2017, the company has rapidly established itself in the industry, with significant operations across Asia and a growing presence in global markets. Specialising in the development of novel drug delivery systems and therapeutics, Ocumension is renowned for its unique approach to treating eye conditions, particularly through its proprietary formulations. The company’s core products aim to enhance patient outcomes and improve the quality of life for those suffering from various ocular disorders. With a commitment to research and development, Ocumension Therapeutics has achieved notable milestones, positioning itself as a key player in the ophthalmology sector. Its dedication to innovation and patient-centric solutions continues to drive its success in the competitive biopharmaceutical landscape.
DitchCarbon Score
How does Ocumension Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ocumension Therapeutics's score of 2 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ocumension Therapeutics's reported carbon emissions
In 2023, Ocumension Therapeutics reported total carbon emissions of approximately 7,246,230 kg CO2e, with Scope 1 emissions at about 2,007,330 kg CO2e and Scope 2 emissions at around 5,238,900 kg CO2e. This marked an increase from 2022, where total emissions were approximately 5,252,800 kg CO2e, with Scope 1 at about 744,900 kg CO2e and Scope 2 at approximately 3,189,850 kg CO2e. The company has not disclosed any specific reduction targets or initiatives as part of its climate commitments. However, it is essential to note that the absence of defined reduction targets may indicate a need for further development in their sustainability strategy. As a global entity headquartered in China, Ocumension Therapeutics operates within an industry increasingly focused on reducing carbon footprints and enhancing environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 21,480 | 00,000 | 000,000 | 0,000,000 |
| Scope 2 | 275,810 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ocumension Therapeutics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
